Neurocrine Biosciences (NASDAQ:NBIX) Receives “Hold” Rating from Needham & Company LLC
Needham & Company LLC reissued their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report report published on Wednesday, Benzinga reports. A number of other analysts have also recently issued reports on the stock. The Goldman Sachs Group increased their price objective on shares of Neurocrine Biosciences from $134.00 […]
More Stories
Fisk Season 3: Release Date, Cast, and Trailer
Fisk, an Australian series, has gone on to win several awards for its stellar cast. With two seasons ahead, fans...
Will South Korean Drama ‘Duty After School’ Return For A Second Season?
Duty After School is a South Korean drama that premiered its first season in 2023. In this article, we explore...
FinTechZoom Review: Insights Into The Financial Technology Company
The growing companies often take assistance from financial services. One such financial service company is FinTechZoom. The article gives an...
The Devil’s Hour Season 2: What Are The Release Dates?
With a Rotten Tomatoes of 95 per cent, The Devil’s Hour amassed a million viewerships in weeks while upgrading fans’s...
Ieq Capital LLC Raises Stock Holdings in LPL Financial Holdings Inc. (NASDAQ:LPLA)
Ieq Capital LLC raised its position in shares of LPL Financial Holdings Inc. (NASDAQ:LPLA – Free Report) by 5.5% in...
Ieq Capital LLC Has $404,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
Ieq Capital LLC cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 10.5% during...